269 related articles for article (PubMed ID: 17960603)
1. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
Ribero D; Wang H; Donadon M; Zorzi D; Thomas MB; Eng C; Chang DZ; Curley SA; Abdalla EK; Ellis LM; Vauthey JN
Cancer; 2007 Dec; 110(12):2761-7. PubMed ID: 17960603
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
4. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Blazer DG; Kishi Y; Maru DM; Kopetz S; Chun YS; Overman MJ; Fogelman D; Eng C; Chang DZ; Wang H; Zorzi D; Ribero D; Ellis LM; Glover KY; Wolff RA; Curley SA; Abdalla EK; Vauthey JN
J Clin Oncol; 2008 Nov; 26(33):5344-51. PubMed ID: 18936472
[TBL] [Abstract][Full Text] [Related]
5. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Klinger M; Tamandl D; Eipeldauer S; Hacker S; Herberger B; Kaczirek K; Dorfmeister M; Gruenberger B; Gruenberger T
Ann Surg Oncol; 2010 Aug; 17(8):2059-65. PubMed ID: 20177795
[TBL] [Abstract][Full Text] [Related]
7. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
[TBL] [Abstract][Full Text] [Related]
8. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
[TBL] [Abstract][Full Text] [Related]
9. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Rubbia-Brandt L; Lauwers GY; Wang H; Majno PE; Tanabe K; Zhu AX; Brezault C; Soubrane O; Abdalla EK; Vauthey JN; Mentha G; Terris B
Histopathology; 2010 Mar; 56(4):430-9. PubMed ID: 20459550
[TBL] [Abstract][Full Text] [Related]
10. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C
J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819
[TBL] [Abstract][Full Text] [Related]
11. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.
Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R
Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017
[TBL] [Abstract][Full Text] [Related]
12. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
13. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T
Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968
[TBL] [Abstract][Full Text] [Related]
14. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Aloia T; Sebagh M; Plasse M; Karam V; Lévi F; Giacchetti S; Azoulay D; Bismuth H; Castaing D; Adam R
J Clin Oncol; 2006 Nov; 24(31):4983-90. PubMed ID: 17075116
[TBL] [Abstract][Full Text] [Related]
15. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
[TBL] [Abstract][Full Text] [Related]
16. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
Kishi Y; Zorzi D; Contreras CM; Maru DM; Kopetz S; Ribero D; Motta M; Ravarino N; Risio M; Curley SA; Abdalla EK; Capussotti L; Vauthey JN
Ann Surg Oncol; 2010 Nov; 17(11):2870-6. PubMed ID: 20567921
[TBL] [Abstract][Full Text] [Related]
17. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response.
Tan MC; Linehan DC; Hawkins WG; Siegel BA; Strasberg SM
J Gastrointest Surg; 2007 Sep; 11(9):1112-9. PubMed ID: 17623263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]